The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
Open accessAbstract
Purpose: Patients with cancer are more likely to file for bankruptcy than the general population, but the impact of severe financial distress on health outcomes among patients with cancer is not known. Methods: We linked Western Washington SEER Cancer Registry records with federal bankruptcy records for the region. By using propensity score matching to account for differences in several demographic and clinical factors between patients who did and did not file for bankruptcy, we then fit Cox proportional hazards models to examine the relationship between bankruptcy filing and survival. Results: Between 1995 and 2009, 231,596 persons were diagnosed with cancer. Patients who filed for bankruptcy (n = 4,728) were more likely to be younger, female, and nonwhite, to have local- or regional- (v distant-) stage disease at diagnosis, and have received treatment. After propensity score matching, 3,841 patients remained in each group (bankruptcy v no bankruptcy). In the matched sample, mean age was 53.0 years, 54% were men, mean income was $49,000, and majorities were white (86%), married (60%), and urban (91%) and had local- or regional-stage disease at diagnosis (84%). Both groups received similar initial treatments. The adjusted hazard ratio for mortality among patients with cancer who filed for bankruptcy versus those who did not was 1.79 (95% CI, 1.64 to 1.96). Hazard ratios varied by cancer type: colorectal, prostate, and thyroid cancers had the highest hazard ratios. Excluding patients with distant-stage disease from the models did not have an effect on results. Conclusion: Severe financial distress requiring bankruptcy protection after cancer diagnosis appears to be a risk factor for mortality. Further research is needed to understand the process by which extreme financial distress influences survival after cancer diagnosis and to find strategies that could mitigate this risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“We examined the balance between baseline covariates before and after propensity score matching by using standardized differences.(6) In the propensity score matched sample, we fit Coxmodels regressing survival on bankruptcy filing status with a robust variance estimator to account for clustering as a result of pair ma…”
MethodRosenbaum, P. R., & Rubin, D. B. (1985) · The American Statistician · doi:10.2307/2683903 · Cited by 4,774
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Rosengren, A., Hawken, S., Ôunpuu, S., Sliwa, K., Zubaid, M., Almahmeed, W. A., Blackett, K. N., Sitthi-amorn, C., Sato, H., & Yusuf, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17019-0 · Cited by 2,414
Cancer Disparities by Race/Ethnicity and Socioeconomic Status
Ward, E., Jemal, A., Cokkinides, V., Singh, G. K., Cardinez, C., Ghafoor, A., & Thun, M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.78 · Cited by 1,801
Zafar, S. Y., Peppercorn, J. M., Schrag, D., Taylor, D. H., Goetzinger, A. M., Zhong, X., & Abernethy, A. P. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0279 · Cited by 1,130
Lynch, J. W., Kaplan, G. A., & Shema, S. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712253372606 · Cited by 876
Ramsey, S., Blough, D., Kirchhoff, A., Kreizenbeck, K., Fedorenko, C., Snell, K., Newcomb, P., Hollingworth, W., & Overstreet, K. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1263 · Cited by 699
Self-citationCost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Rosenbaum, P. R. (2002) · Springer Series in Statistics · doi:10.1007/978-1-4757-3692-2_1 · Cited by 484
Cited by
Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, A. B., Mariotto, A., Lake, A. J., Wilson, R., Sherman, R. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx030 · Cited by 1,556
Knaul, F. M., Farmer, P. E., Krakauer, E. L., De Lima, L., Bhadelia, A., Jiang Kwete, X., Arreola-Ornelas, H., Gómez-Dantés, O., Rodriguez, N. M., Alleyne, G. A. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32513-8 · Cited by 1,456
de Souza, J. A., Yap, B. J., Wroblewski, K., Blinder, V., Araújo, F. S., Hlubocky, F. J., Nicholas, L. H., O'Connor, J. M., Brockstein, B., Ratain, M. J., et al. (2017) · Cancer · doi:10.1002/cncr.30369 · Cited by 917
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
Financial Hardships Experienced by Cancer Survivors: A Systematic Review
Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D., & Yabroff, K. R. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw205 · Cited by 864
Triple negative breast cancer: Pitfalls and progress
Zagami, P., & Carey, L. A. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00468-0 · Cited by 839
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Inequality and the health-care system in the USA
Dickman, S. L., Himmelstein, D. U., & Woolhandler, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30398-7 · Cited by 656
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 601
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., Goff, L., Gupta, S., Guy, J., Harris, W. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02672 · Cited by 570
The high price of anticancer drugs: origins, implications, barriers, solutions
Prasad, V., De Jesús, K., & Mailankody, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.31 · Cited by 442
Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes
Smith, G. L., Lopez-Olivo, M. A., Advani, P. G., Ning, M. S., Geng, Y., Giordano, S. H., & Volk, R. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7305 · Cited by 437
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6211 · Cited by 426
“as bankruptcy, these financial effects can be associated with increased mortality.(32) The financial consequences associated with diagnostic and treatment choices for patients with cancer who have FN rarely are associated with significant costs.”
BackgroundFinancial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies
Lentz, R., Benson, A. B., & Kircher, S. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25374 · Cited by 336
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 312
Witte, J., Mehlis, K., Surmann, B., Lingnau, R., Damm, O., Greiner, W., & Winkler, E. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz140 · Cited by 271
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach
Smith, G. L., Banegas, M. P., Acquati, C., Chang, S., Chino, F., Conti, R. M., Greenup, R. A., Kroll, J. L., Liang, M. I., Pisu, M., et al. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21730 · Cited by 260
Self-citationThe state of Cancer Care in America, 2017: a report by the American Society of Clinical Oncology
The American Society of Clinical Oncology (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.020743 · Cited by 204
Ehsan, A. N., Wu, C. A., Minasian, A., Singh, T., Bass, M., Pace, L., Ibbotson, G. C., Bempong-Ahun, N., Pusic, A., Scott, J. W., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55388 · Cited by 183
Considerations for treatment duration in responders to immune checkpoint inhibitors
Marron, T. U., Ryan, A. E., Reddy, S. M., Kaczanowska, S., Younis, R. H., Thakkar, D., Zhang, J., Bartkowiak, T., Howard, R., Anderson, K. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001901 · Cited by 137
Correlates of financial toxicity in adult cancer patients and their informal caregivers
Sadigh, G., Switchenko, J., Weaver, K. E., Elchoufi, D., Meisel, J., Bilen, M. A., Lawson, D., Cella, D., El-Rayes, B., & Carlos, R. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06424-1 · Cited by 84
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
Soliman, H., Shah, V., Srkalovic, G., Mahtani, R., Levine, E., Mavromatis, B., Srinivasiah, J., Kassar, M., Gabordi, R., Qamar, R., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6534-z · Cited by 65
Uppal, N., Cunningham (nee Lubitz), C., & James, B. (2022) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2022.0660 · Cited by 61
Alternative payment and care‐delivery models in oncology: A systematic review
Aviki, E. M., Schleicher, S. M., Mullangi, S., Matsoukas, K., & Korenstein, D. (2018) · Cancer · doi:10.1002/cncr.31367 · Cited by 60
Jiang, X., Sun, J., Song, R., Wang, Y., Li, J., & Shi, R. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1253266 · Cited by 43
Financial distress and its associated burden in couples coping with an advanced cancer
Kroll, J. L., Kim, S., Cho, D., Weathers, S.-P., Chen, A. B., Smith, G., Bruera, E., & Milbury, K. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06758-w · Cited by 26
Doherty, M., Miller-Sonet, E., Gardner, D., & Epstein, I. (2019) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2018.1504851 · Cited by 22
Wang, S. E., Haupt, E. C., Nau, C., Werch, H., McMullen, C., Lynn, J., Shen, E., Mularski, R. A., Nguyen, H. Q., & the HomePal Research Group (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07286-3 · Cited by 17
“Financial distress is in turn associated with poor quality of life, 13 depression, 14 and increased mortality.(15) Beyond cancer, for patients living with advanced illness, Emanuel and colleagues(16) identified underlying factors such as old age, low income, poor physical function, and Key Message”
BackgroundAssociation of major adverse financial events and later-stage cancer diagnosis in the United States.
Warren, J. L., Mariotto, A. B., Stevens, J., Davidoff, A. J., Shankaran, V., Ward, K. C., Wu, X.-C., Schwartz, S. M., Penberthy, L., & Yabroff, K. R. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01067 · Cited by 7
Self-citation
Metadata
- Authors
- Ramsey, S. D., Bansal, A., Fedorenko, C. R., Blough, D. K., Overstreet, K. A., Shankaran, V., & Newcomb, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-03-20
- Volume
- 34
- Issue
- 9
- Pages
- 980-986
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2266198524
- Cited by
- 912
- References
- 22
- FWCI
- 144.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.